Lifecore Biomedical, Inc. LFCR
NASDAQ
| 06/30/2026 | 09/30/2025 | 09/30/2025 | 05/25/2025 | 05/25/2025 | |
|---|---|---|---|---|---|
| Net Income | 58.91% | -771.05% | -771.05% | 92.23% | 92.23% |
| Total Depreciation and Amortization | 8.87% | 3.50% | 3.50% | -7.80% | -7.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.05% | 62.93% | 62.93% | -65.68% | -65.68% |
| Change in Net Operating Assets | -255.69% | 162.18% | 162.18% | 57.95% | 57.95% |
| Cash from Operations | -146.57% | -67.05% | -67.05% | 345.58% | 345.58% |
| Capital Expenditure | 54.11% | 17.17% | 17.17% | 61.57% | 61.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 54.11% | 17.17% | 17.17% | -235.82% | -235.82% |
| Total Debt Issued | -23.08% | -90.59% | -90.59% | -- | -- |
| Total Debt Repaid | 23.08% | 90.36% | 90.36% | -1,952.13% | -1,952.13% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -576.02% | -576.02% | -28.57% | -28.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.03% | -- | -- | -113.79% | -113.79% |
| Cash from Financing | -232.81% | -245.27% | -245.27% | 94.07% | 94.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.86% | -147.86% | -147.86% | 170.53% | 170.53% |